Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials
- PMID: 23126307
- DOI: 10.1111/j.1471-0528.2012.03493.x
Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials
Abstract
Objective: To study the effect of aspirin in the prevention of pre-eclampsia in high-risk women.
Design: Randomised, double-blinded, placebo-controlled trial.
Setting: Maternity clinics in ten Finnish hospitals participating in the PREDO Project.
Sample: A total of 152 women with risk factors for pre-eclampsia and abnormal uterine artery Doppler velocimetry.
Methods: Participants were randomised to start either aspirin 100 mg/day or placebo at 12 + 0 to 13 + 6 weeks + days of gestation. Because of the limited power of this trial, we also conducted a meta-analysis of randomised controlled trials that included data on 346 women with abnormal uterine artery Doppler flow velocimetry, and aspirin 50-150 mg/day started at or before 16( ) weeks of gestation.
Main outcome measure: Pre-eclampsia, gestational hypertension and birthweight standard deviation (SD) score. Outcome measures for the meta-analysis were pre-eclampsia, severe pre-eclampsia, preterm (diagnosed <37 + 0 weeks of gestation) and term pre-eclampsia.
Results: From the 152 randomised women, 121 were included in the final analysis. Low-dose aspirin did not reduce the rate of pre-eclampsia (relative risk [RR] 0.7, 95% CI 0.3-1.7); gestational hypertension (RR 1.6, 95% CI 0.6-4.2); early-onset pre-eclampsia (diagnosed <34 + 0 weeks of gestation) (RR 0.2, 95% CI 0.03-2.1); or severe pre-eclampsia (RR 0.4, 95% CI 0.1-1.3); and the results were not statistically significant in an intention-to-treat analysis. However, our meta-analysis, including the current data, suggested that low-dose aspirin initiated before 16 weeks of gestation reduces the risk of pre-eclampsia (RR 0.6, 95% CI 0.4-0.8) and severe pre-eclampsia (RR 0.3, 95% CI 0.1-0.7).
Conclusions: Our trial showed no statistically significant effect of aspirin in preventing pre-eclampsia in high-risk women. However, our meta-analysis suggested that aspirin may reduce the incidence of pre-eclampsia.
© 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2012 RCOG.
Comment in
-
Aspirin in the prevention of pre-eclampsia in high-risk women.BJOG. 2013 May;120(6):773. doi: 10.1111/1471-0528.12135. BJOG. 2013. PMID: 23565952 No abstract available.
-
Initiation of aspirin in early gestation for the prevention of pre-eclampsia.BJOG. 2013 May;120(6):773-4. doi: 10.1111/1471-0528.12170. BJOG. 2013. PMID: 23565953 No abstract available.
-
Initiation of aspirin in early gestation for the prevention of pre-eclampsia.BJOG. 2013 May;120(6):774-5. doi: 10.1111/1471-0528.12169. BJOG. 2013. PMID: 23565954 No abstract available.
Similar articles
-
Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation.Ultrasound Obstet Gynecol. 2003 Sep;22(3):233-9. doi: 10.1002/uog.218. Ultrasound Obstet Gynecol. 2003. PMID: 12942493 Clinical Trial.
-
Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 2).BJOG. 2003 May;110(5):485-91. doi: 10.1046/j.1471-0528.2003.t01-1-02097.x. BJOG. 2003. PMID: 12742333 Clinical Trial.
-
Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis.J Obstet Gynaecol Can. 2009 Sep;31(9):818-826. doi: 10.1016/S1701-2163(16)34300-6. J Obstet Gynaecol Can. 2009. PMID: 19941706 Review.
-
Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin.Br J Obstet Gynaecol. 1996 Jul;103(7):625-9. doi: 10.1111/j.1471-0528.1996.tb09829.x. Br J Obstet Gynaecol. 1996. PMID: 8688387 Clinical Trial.
-
Antiplatelet agents for preventing and treating pre-eclampsia.Cochrane Database Syst Rev. 2000;(2):CD000492. doi: 10.1002/14651858.CD000492. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2007 Jul 18;(2):CD000492. doi: 10.1002/14651858.CD000492.pub2. PMID: 10796208 Updated. Review.
Cited by
-
The optimal dosage of aspirin for preventing preeclampsia in high-risk pregnant women: A network meta-analysis of 23 randomized controlled trials.J Clin Hypertens (Greenwich). 2024 May;26(5):455-464. doi: 10.1111/jch.14821. Epub 2024 Apr 29. J Clin Hypertens (Greenwich). 2024. PMID: 38683867 Free PMC article.
-
The Role of Acetylsalicylic Acid in the Prevention of Pre-Eclampsia, Fetal Growth Restriction, and Preterm Birth.Dtsch Arztebl Int. 2023 Sep 15;120(37):617-626. doi: 10.3238/arztebl.m2023.0133. Dtsch Arztebl Int. 2023. PMID: 37378599 Free PMC article. Review.
-
Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention.Curr Cardiol Rev. 2023;19(6):9-22. doi: 10.2174/1573403X19666230502163828. Curr Cardiol Rev. 2023. PMID: 37132104
-
Preeclampsia and aspirin.Obstet Gynecol Sci. 2023 May;66(3):120-132. doi: 10.5468/ogs.22261. Epub 2023 Mar 16. Obstet Gynecol Sci. 2023. PMID: 36924072 Free PMC article.
-
Aspirin 75 mg to prevent preeclampsia in high-risk pregnancies: a retrospective real-world study in China.Eur J Med Res. 2023 Feb 2;28(1):56. doi: 10.1186/s40001-023-01024-7. Eur J Med Res. 2023. PMID: 36732824 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical